Перейти к контенту
Main image
Печать
ANTI-LRRK2 (C-TERMINAL REGION)
Кат. №: L9918-200UL
Производитель: Sigma-Aldrich
Кол-во:
Цена по запросу
Товар оформляется под заказ
Печать
ANTI-LRRK2 (C-TERMINAL REGION)
Main image
Кат. №: L9918-200UL
Производитель: Sigma-Aldrich
Кол-во:
Цена по запросу
Товар оформляется под заказ
Main image
Печать
ANTI-LRRK2 (C-TERMINAL REGION)
Кат. №: L9918-200UL
Производитель: Sigma-Aldrich
Кол-во:
Цена по запросу
Товар оформляется под заказ
Description_x000D_ General description_x000D_ Leucine-rich repeat protein kinase 2 (LRRK2) comprises multiple domains, including a leucine-rich repeat (LRR) domain, a Roc (Ras of complex proteins) GTPase domain followed by a C-terminal of ROC (COR) domain, a Ser/Thr kinase domain and a C-terminal Trp-Asp-40 (WD40) domain. The N-terminal region (?900 amino acids) contains ankyrin (ANK) repeats. The LRRK2 homologue LRRK1 shares domain structure similarity with LRRK2._x000D_ Specificity_x000D_ Anti-LRRK2 (C-terminal region) antibody is specific for LRRK2 (approx. 240 kDa) in mice, rats and humans._x000D_ Application_x000D_ Anti-LRRK2 (C-terminal region) antibody is suitable for use in western blot (2-4 μg/mL using HEK-293T cells expressing human LRRK2, and using S2 fractions of rat and mouse brain extracts)._x000D_ Physical form_x000D_ Solution in 0.01 M phos­phate buffered saline, pH 7.4, containing 15 mM sodium azide._x000D_ Disclaimer_x000D_ Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals._x000D_ Biochem/physiol Actions_x000D_ LRRK2 is a μLtimeric kinase that also functions as a GTPase. LRRK2 activates a calcium/calmodulin-dependent protein kinase kinase (CaMKK)-β/AMPK signaling pathway and subsequently mediates autophagy. Genetic alterations in LRRK2 cause late-onset Parkinson′s disease . Anti-LRRK2 (C-terminal region) antibody is specific for LRRK2 (approx. 240 kDa) in mice, rats and humans. Staining of the LRRK2 band by immunoblotting is specifically inhibited by the LRRK2 immunizing peptide._x000D_ LRRK2 mRNA is expressed throughout the brain predominantly within regions of the basal ganglia that are associated with Parkinson′s disease. The presence of multiple protein interaction domains suggests that in addition to its kinase and GTPase activities, LRRK2 may serve as a scaffold protein for the assembly of multiprotein signaling complex. R1441C mutation has been shown to disrupt GTPase activity. G2019S and R1441C, both associated with increased kinase activity.
Related Categories
Alphabetical Index, Antibodies, Antibodies for Parkinson’s Disease Research, Cell Biology, Cell Signaling and Neuroscience, LRR-LZ, Neurobiology, Neuroscience, Parkinson′s Disease, Primary Antibodies, Products for Neurodegenerative Disease ResearchMore... conjugate
Дорогой клиент, на сайте внедрена нейросеть для сбора информации о товаре. Это может привести к незначительным расхождениям в характеристиках продукции.
Description_x000D_ General description_x000D_ Leucine-rich repeat protein kinase 2 (LRRK2) comprises multiple domains, including a leucine-rich repeat (LRR) domain, a Roc (Ras of complex proteins) GTPase domain followed by a C-terminal of ROC (COR) domain, a Ser/Thr kinase domain and a C-terminal Trp-Asp-40 (WD40) domain. The N-terminal region (?900 amino acids) contains ankyrin (ANK) repeats. The LRRK2 homologue LRRK1 shares domain structure similarity with LRRK2._x000D_ Specificity_x000D_ Anti-LRRK2 (C-terminal region) antibody is specific for LRRK2 (approx. 240 kDa) in mice, rats and humans._x000D_ Application_x000D_ Anti-LRRK2 (C-terminal region) antibody is suitable for use in western blot (2-4 μg/mL using HEK-293T cells expressing human LRRK2, and using S2 fractions of rat and mouse brain extracts)._x000D_ Physical form_x000D_ Solution in 0.01 M phos­phate buffered saline, pH 7.4, containing 15 mM sodium azide._x000D_ Disclaimer_x000D_ Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals._x000D_ Biochem/physiol Actions_x000D_ LRRK2 is a μLtimeric kinase that also functions as a GTPase. LRRK2 activates a calcium/calmodulin-dependent protein kinase kinase (CaMKK)-β/AMPK signaling pathway and subsequently mediates autophagy. Genetic alterations in LRRK2 cause late-onset Parkinson′s disease . Anti-LRRK2 (C-terminal region) antibody is specific for LRRK2 (approx. 240 kDa) in mice, rats and humans. Staining of the LRRK2 band by immunoblotting is specifically inhibited by the LRRK2 immunizing peptide._x000D_ LRRK2 mRNA is expressed throughout the brain predominantly within regions of the basal ganglia that are associated with Parkinson′s disease. The presence of multiple protein interaction domains suggests that in addition to its kinase and GTPase activities, LRRK2 may serve as a scaffold protein for the assembly of multiprotein signaling complex. R1441C mutation has been shown to disrupt GTPase activity. G2019S and R1441C, both associated with increased kinase activity.
Related Categories
Alphabetical Index, Antibodies, Antibodies for Parkinson’s Disease Research, Cell Biology, Cell Signaling and Neuroscience, LRR-LZ, Neurobiology, Neuroscience, Parkinson′s Disease, Primary Antibodies, Products for Neurodegenerative Disease ResearchMore... conjugate
Дорогой клиент, на сайте внедрена нейросеть для сбора информации о товаре. Это может привести к незначительным расхождениям в характеристиках продукции.